GLPG Relative Valuation - Galapagos NV - Alpha Spread

Galapagos NV
NASDAQ:GLPG

Watchlist Manager
Galapagos NV Logo
Galapagos NV
NASDAQ:GLPG
Watchlist
Price: 30.045 USD -0.78%
Market Cap: 2B USD
Have any thoughts about
Galapagos NV?
Write Note

Relative Value

The Relative Value of one GLPG stock under the Base Case scenario is 28.061 USD. Compared to the current market price of 30.045 USD, Galapagos NV is Overvalued by 7%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GLPG Relative Value
Base Case
28.061 USD
Overvaluation 7%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
88
vs Industry
77
Median 3Y
5.4
Median 5Y
6.9
Industry
7.7
Forward
6
vs History
31
vs Industry
11
Median 3Y
-13.8
Median 5Y
-13.8
Industry
23.9
Forward
-110.6
vs History
vs Industry
Median 3Y
-5.3
Median 5Y
-5.3
Industry
22.2
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-4.9
Industry
24
vs History
92
vs Industry
69
Median 3Y
1
Median 5Y
1.2
Industry
2.5
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-2.1
Industry
7.4
Forward
-5.5
vs History
vs Industry
Median 3Y
-3
Median 5Y
-23.3
Industry
8.5
vs History
44
vs Industry
8
Median 3Y
12.9
Median 5Y
12.1
Industry
5.1
Forward
13.9
vs History
58
vs Industry
8
Median 3Y
9.7
Median 5Y
9.4
Industry
4.7
Forward
12.9
vs History
12
vs Industry
13
Median 3Y
3.2
Median 5Y
2.6
Industry
6.6
vs History
15
vs Industry
10
Median 3Y
3.1
Median 5Y
2.4
Industry
4.7
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-2.6
Industry
4.7

Multiples Across Competitors

GLPG Competitors Multiples
Galapagos NV Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
BE
Galapagos NV
NASDAQ:GLPG
2B USD 3.1 5.3 12.7 8.6
US
Abbvie Inc
NYSE:ABBV
340.3B USD 6.2 64.3 15.7 24
US
Amgen Inc
NASDAQ:AMGN
181.1B USD 5.9 57.8 20.2 36.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
129.3B USD 9.6 29.9 26.3 29.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.8B USD 12 -252.7 26.9 28.2
US
Epizyme Inc
F:EPE
94.1B EUR 1 975 -504 -548.8 -534.2
US
Gilead Sciences Inc
NASDAQ:GILD
104.7B USD 3.8 99.5 9.5 12
AU
CSL Ltd
ASX:CSL
142.3B AUD 6.5 36.4 22.3 27.8
US
Seagen Inc
F:SGT
39.3B EUR 19 -58.3 -62.8 -56.7
US
Palatin Technologies Inc
LSE:0KF3
38.2B USD 6 466.9 -1 161.2 -1 176.8 -1 164.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
35.7B USD 15.2 -489.2 215.5 331.7
P/E Multiple
Earnings Growth
BE
Galapagos NV
NASDAQ:GLPG
Average P/E: 48.9
5.3
N/A
US
Abbvie Inc
NYSE:ABBV
64.3
406%
US
Amgen Inc
NASDAQ:AMGN
57.8
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.9
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -252.7
38%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -504 N/A
US
Gilead Sciences Inc
NASDAQ:GILD
99.5
71%
AU
CSL Ltd
ASX:CSL
36.4
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.3 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 161.2 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -489.2 N/A
EV/EBITDA Multiple
EBITDA Growth
BE
Galapagos NV
NASDAQ:GLPG
Average EV/EBITDA: 43.6
12.7
N/A
US
Abbvie Inc
NYSE:ABBV
15.7
28%
US
Amgen Inc
NASDAQ:AMGN
20.2
57%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
26.3
47%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.9
39%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -548.8 N/A
US
Gilead Sciences Inc
NASDAQ:GILD
9.5
10%
AU
CSL Ltd
ASX:CSL
22.3
45%
US
S
Seagen Inc
F:SGT
Negative Multiple: -62.8 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 176.8 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
215.5
N/A

See Also

Discover More
Back to Top